Anti-arrhythmic strategies for atrial fibrillation: The role of computational modeling in discovery, development, and

Eleonora Grandi1, Mary M Maleckar2

  • 1Department of Pharmacology, University of California Davis, Davis, USA.

Pharmacology & Therapeutics
|September 11, 2016
PubMed

Insights

Computational modeling offers a quantitative framework to understand atrial fibrillation (AF) mechanisms and test therapies. This approach aids in developing new treatments for AF, a common heart arrhythmia linked to stroke and heart failure.

Area of Science:

  • Computational Biology
  • Cardiovascular Research
  • Medical Imaging and Modeling

Background:

  • Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia, increasing stroke and heart failure risk.
  • Current AF treatments focus on stroke prevention (anticoagulation) and rate/rhythm control, but rate control is often symptomatically insufficient.
  • Rhythm control strategies include antiarrhythmic drugs, electrical cardioversion, and ablation.

Purpose of the Study:

  • To demonstrate how computational modeling can integrate multiscale data for a quantitative understanding of AF.
  • To explore the use of computational models in identifying and testing pharmacological and electrical interventions for AF.
  • To highlight the role of computational modeling in supporting clinical decisions for AF management.

Main Methods:

  • Review of existing computational modeling approaches applied to atrial fibrillation research.
  • Integration of multiscale data within quantitative frameworks.
  • Analysis of how modeling aids in evaluating therapeutic strategies.

Main Results:

  • Computational modeling provides insights into the complex, multiscale mechanisms underlying AF.
  • Modeling facilitates the identification and preclinical testing of novel pharmacological and electrical therapies.
  • The quantitative framework supports informed clinical decision-making for AF patients.

Conclusions:

  • Computational modeling is a valuable tool for advancing AF research and therapy development.
  • The field has evolved significantly, contributing to the preclinical development pipeline.
  • Future directions include addressing challenges in multiscale data integration and model validation for clinical application.

Related Concept Videos

Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
577
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.8K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
3.9K
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
3.5K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.2K
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
801